| Title |
Agomelatine: The evidence for its place in the treatment of depression
|
|---|---|
| Published in |
Core Evidence, August 2009
|
| DOI | 10.2147/ce.s6005 |
| Pubmed ID | |
| Authors |
Daniela Eser, Thomas C Baghai, Hans-Jürgen Möller |
| Abstract |
Depressive disorders are among the main causes of disability due to disease. In spite of recent progress in the pharmacotherapy of depression, there is still a high nonresponse rate of approximately 30% to the first antidepressant treatment. Furthermore, the latency of several weeks until sufficient clinical improvement and the risk of side effects remain unresolved problems. Therefore, there is still further need for the development of new antidepressants. In the last years a variety of melatonin receptor agonists have been synthesized and evaluated for the treatment of sleep disorders. Animal studies suggested that agomelatine (S-20098), a synthetic melatonergic MT(1) and MT(2) receptor agonist with serotonin receptor antagonistic properties, may have additional activating properties and may represent a new approach in the treatment of depression. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 63 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 2% |
| Germany | 1 | 2% |
| Unknown | 61 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 14 | 22% |
| Student > Master | 6 | 10% |
| Professor | 6 | 10% |
| Student > Ph. D. Student | 5 | 8% |
| Student > Bachelor | 4 | 6% |
| Other | 12 | 19% |
| Unknown | 16 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 20 | 32% |
| Agricultural and Biological Sciences | 7 | 11% |
| Psychology | 5 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 6% |
| Neuroscience | 3 | 5% |
| Other | 6 | 10% |
| Unknown | 18 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 April 2019.
All research outputs
#8,262,981
of 25,374,917 outputs
Outputs from Core Evidence
#36
of 77 outputs
Outputs of similar age
#40,961
of 122,459 outputs
Outputs of similar age from Core Evidence
#2
of 4 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one has received more attention than most of these and is in the 66th percentile.
So far Altmetric has tracked 77 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one has gotten more attention than average, scoring higher than 53% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 122,459 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.